Relevant bibliographies by topics / Travel=2016-12-11 / Journal articles
To see the other types of publications on this topic, follow the link: Travel=2016-12-11.

Journal articles on the topic 'Travel=2016-12-11'

Author: Grafiati
Published: 11 December 2022
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Travel=2016-12-11.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Byington, Carrie L., Krow Ampofo, Tammi Lewis, et al. "Arboviral Infections Following the 2016 Olympic and Paralympic Games in a Cohort of US Athletes and Support Staff." Open Forum Infectious Diseases 4, suppl_1 (2017): S64. http://dx.doi.org/10.1093/ofid/ofx162.152.

Full text
Abstract:
Abstract Background The 2016 Olympic and Paralympic games were held in Brazil after the peak of an explosive Zika virus (ZIKV) outbreak. The risk to US athletes and support staff of travel-associated ZIKV and other arboviral infections was unknown but concern was high. Methods Individuals traveling with the US Olympic Committee (USOC), including Olympic and Paralympic athletes and support staff were enrolled. Participants provided a pre- and post-travel (2–12 weeks) blood samples, and were also counseled about mosquito avoidance. Participants completed pre- and post-travel surveys detailing de
APA, Harvard, Vancouver, ISO, and other styles
2

Rymkiewicz, Grzegorz, Joanna Romejko-Jarosinska, Katarzyna Blachnio, et al. "DA-EPOCH-R Is an Effective Regimenin High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2/MYC/BCL6 Status and Expression." Blood 128, no. 22 (2016): 1754. http://dx.doi.org/10.1182/blood.v128.22.1754.1754.

Full text
Abstract:
Abstract Background: MYC, BCL2 and BCL6 are known to be altered in high grade B-cell lymphoma (HGBL). Double/triple-hit lymphomas (D/THLs) are characterized by chromosomal rearrangementsof MYC, BCL2 and/or BCL6. D/THLs have been included in the updated 2016 WHO classification, as a new category of "High grade B-cell lymphoma with rearrangements" (HGBL-R) or Diffuse Large B-cell lymphoma (DLBCL) entity, depending on morphology/cytogenetic features. BCL2 protein is expressed in a much higher proportion of DLBCL and HGBL, not otherwise specified (HGBL,NOS), and is often associated with a concomit
APA, Harvard, Vancouver, ISO, and other styles
3

Scholes, Shaun, and Jennifer S. Mindell. "Income-based inequalities in self-reported moderate-to-vigorous physical activity among adolescents in England and the USA: a cross-sectional study." BMJ Open 11, no. 2 (2021): e040540. http://dx.doi.org/10.1136/bmjopen-2020-040540.

Full text
Abstract:
ObjectiveQuantify income-based inequalities in self-reported moderate-to-vigorous physical activity (MVPA) in England and the USA by sex.DesignPopulation-based cross-sectional study.Participants4019 adolescents aged 11–15 years in England (Health Survey for England 2008, 2012, 2015) and 4312 aged 12–17 years in the US (National Health and Nutrition Examination Survey 2007–2016).Main outcome measuresThree aspects of MVPA: (1) doing any, (2) average min/day (MVPA: including those who did none) and (3) average min/day conditional on participation (MVPA active). Using hurdle models, inequalities w
APA, Harvard, Vancouver, ISO, and other styles
4

Santo, Samuel Christoper, and Ni Made Satvika Iswari. "Design and Development of Animal Recognition Application Using Gamification and Sattolo Shuffle Algorithm on Android Platform." International Journal of New Media Technology 4, no. 1 (2017): 46–53. http://dx.doi.org/10.31937/ijnmt.v4i1.538.

Full text
Abstract:
Information and communication technology has been developed rapidly and affectedvarious aspects such as propagation of information and marketing strategy of tourist attraction. KebunBinatang Ragunan is one of tourist attraction in Indonesia. Aside from recreation area, Kebun BinatangRagunan can be a place to learn animals. However, learning animals itself tends to be less attractive and less interactive. Therefore, an application was developed as one of animal learning media to increase touristmotivation. The application developed in form of quiz game by using gamification like achievement to
APA, Harvard, Vancouver, ISO, and other styles
5

Medalla, Felicita, Louise Francois Watkins, Michael Hughes, et al. "165. Emergence of Extensively Drug-Resistant Salmonella enterica Serotype Typhi Infections—United States, 2008–2020." Open Forum Infectious Diseases 8, Supplement_1 (2021): S99—S100. http://dx.doi.org/10.1093/ofid/ofab466.165.

Full text
Abstract:
Abstract Background Typhoid fever, caused by Salmonella Typhi, is fatal in 12%–30% of patients not treated with appropriate antibiotics. In 2016, a large outbreak of extensively drug-resistant (XDR) Typhi infections began in Pakistan with cases reported globally, including the United States. In 2021, the Centers for Disease Control and Prevention (CDC) issued a health advisory on XDR infections among U.S. residents without international travel. We describe resistance of Typhi infections diagnosed in the United States to help guide treatment decisions. Methods Typhoid fever is a nationally noti
APA, Harvard, Vancouver, ISO, and other styles
6

Fischer, Kirsten, Othman Al-Sawaf, Anna-Maria Fink, et al. "Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)." Blood 128, no. 22 (2016): 2054. http://dx.doi.org/10.1182/blood.v128.22.2054.2054.

Full text
Abstract:
Abstract Introduction The BCL-2 inhibitor venetoclax has yielded promising results in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), both as monotherapy and in combination with rituximab. The CLL14 trial is a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions. Prior to opening the randomized phase, a run-in phase was performed to assess the tolerability of obinutuzumab and venetoclax
APA, Harvard, Vancouver, ISO, and other styles
7

Boquoi, Amelie, Soraya Magdalena Banahan, Judith Strapatsas, et al. "Therapy-Related Myeloid Neoplasms Following Treatment for Multiple Myeloma : A Single-Center Analysis." Blood 134, Supplement_1 (2019): 4261. http://dx.doi.org/10.1182/blood-2019-122598.

Full text
Abstract:
Introduction Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) comprise late complications following mutagenic treatment. Limited data is available on the outcome of patients (pts) developing therapy-related MDS and AML (tMDS, tAML) after treatment for multiple myeloma (MM). Methods From 1976 to 2011, 3814 pts were entered into the Düsseldorf MDS registry. We identified 200 pts with tMDS or tAML. Of those, 41 pts had also been diagnosed with multiple myeloma (mm-MDS/AML). We compared these 41 pts to pts with de novo MDS (n=3614) and to pts with tMDS with other underlying disease
APA, Harvard, Vancouver, ISO, and other styles
8

Cramer, Paula, Julia von Tresckow, Jasmin Bahlo, et al. "Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)." Blood 128, no. 22 (2016): 2044. http://dx.doi.org/10.1182/blood.v128.22.2044.2044.

Full text
Abstract:
Abstract Introduction: Several targeted agents have been introduced for CLL, including the CD20-antibody obinutuzumab (GA101, G) and the Bcl-2 antagonist venetoclax (ABT-199, A). Both agents show exciting efficacy which comes at the cost of an increased risk of TLS and IRRs and mandate several safety precautions especially during the first treatment cycles and in patients (pts) with a higher tumor load and/or renal insufficiency. Based on the theoretical "sequential triple-T" concept [Hallek M., Blood 2013; 122(23): 3723-34] of a tailored and targeted treatment aiming for total eradication of
APA, Harvard, Vancouver, ISO, and other styles
9

Roy, Denis-Claude, Silvy Lachance, Jean Roy, et al. "Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL." Blood 128, no. 22 (2016): 1226. http://dx.doi.org/10.1182/blood.v128.22.1226.1226.

Full text
Abstract:
Abstract Introduction. Haploidentical donors may resolve the shortage of available HLA-matched donors for the treatment of patients with blood cancers in need of a hematopoietic stem cell transplantation (HSCT). However, to prevent graft-versus-host disease (GVHD), haploidentical HSCT requires alloreactive T-cell depletion or suppression. We developed an ex vivo cell treatment strategy that allows additional donor lymphocytes to be infused post-HSCT without inducing severe GVHD and maintaining reactivity against viruses and leukemic cells. Patients and Methods. In this open-label, multicenter
APA, Harvard, Vancouver, ISO, and other styles
10

Praveen, Kumar, Karthi Nallasamy, Muralidharan Jayashree, and Praveen Kumar. "Brought in dead cases to a tertiary referral paediatric emergency department in India: a prospective qualitative study." BMJ Paediatrics Open 4, no. 1 (2020): e000606. http://dx.doi.org/10.1136/bmjpo-2019-000606.

Full text
Abstract:
ObjectivesBrought in dead (BID) presentation is profoundly related to prehospital variables including disease-related determinants and social and system-related factors. Identifying these factors would help us recognise various gaps in health services.SettingTertiary paediatric emergency department (ED) in north India.PatientsChildren aged 12 years or younger presented in cardiac arrest between April 2016 and March 2017 were prospectively enrolled irrespective of outcome of cardiopulmonary resuscitation (CPR). Data were collected from multiple sources including referral documents, direct inter
APA, Harvard, Vancouver, ISO, and other styles
11

Taylor, Monica, Liam J. Caffery, Paul A. Scuffham, and Anthony C. Smith. "Economic modelling of telehealth substitution of face-to-face specialist outpatient consultations for Queensland correctional facilities." Australian Health Review 42, no. 5 (2018): 522. http://dx.doi.org/10.1071/ah17135.

Full text
Abstract:
Objective The provision of healthcare services to inmates in correctional facilities is costly and resource-intensive. This study aimed to estimate the costs of transporting prisoners from 11 Queensland correctional facilities to the Princess Alexandra Hospital Secure Unit (PAHSU) in Brisbane for non-urgent specialist outpatient consultations and identify the cost consequences that would result from the substitution of face-to-face visits with telehealth consultations. Methods A 12-month retrospective review of patient activity at the PAHSU was conducted to obtain the number of transfers per c
APA, Harvard, Vancouver, ISO, and other styles
12

Atilla, Erden, Pervin Topcuoglu, Erman Akkus, et al. "Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients." Blood 132, Supplement 1 (2018): 3472. http://dx.doi.org/10.1182/blood-2018-99-118314.

Full text
Abstract:
Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant and non-malignant hematological diseases. The impact of ABO mismatch on outcome following transplantation remains controversial. In this study, our aim is to define effects of ABO mismatch on engraftment, graft vs host disease, relapse free survival (RFS) and overall survival (OS) in patients who underwent allo-HSCT. Patients and Methods: Between 1988 and 2016, we retrospectively identified 1016 patients who underwent allo-HSCT at Ankara University School of Medicine, Departm
APA, Harvard, Vancouver, ISO, and other styles
13

Eichhorst, Barbara F., Jasmin Bahlo, Christian Maurer, et al. "Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)." Blood 128, no. 22 (2016): 4382. http://dx.doi.org/10.1182/blood.v128.22.4382.4382.

Full text
Abstract:
Abstract Introduction: FCR is still the standard frontline regimen for physically fit CLL pts without TP53 alteration. The international phase III CLL10 study demonstrated the inferiority of BR in comparison to FCR in this population. In order to evaluate long-term outcome and toxicity we performed an updated analysis after extended observation time. Methods and Patients: 561 pts were randomized as previously published (Eichhorst B et al., Lancet Oncol 2016). 282 and 279 pts were randomized to receive either 6 courses of FCR or BR respectively. After the end of treatment pts were followed 3-mo
APA, Harvard, Vancouver, ISO, and other styles
14

Seymour, John F., Matthew S. Davids, Andrew W. Roberts, et al. "Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia." Blood 128, no. 22 (2016): 4395. http://dx.doi.org/10.1182/blood.v128.22.4395.4395.

Full text
Abstract:
Abstract Background: Venetoclax (VEN) is a potent, highly selective, orally bioavailable small-molecular BCL2 inhibitor that is FDA-approved for patients (pts) with chronic lymphocytic leukemia (CLL) that harbors del(17p) and who have received ≥1 prior therapy. VEN monotherapy induces objective response in ~80% of pts (16-20% complete remission by investigator) with relapsed/refractory (R/R) CLL, including del(17p) CLL (Roberts et al, 2016; Stilgenbauer et al, 2016). Safety of VEN monotherapy was evaluated using an integrated dataset from pts with CLL. Methods: Pts were included if they receiv
APA, Harvard, Vancouver, ISO, and other styles
15

Drew, Michael, Nicole Vlahovich, David Hughes, et al. "Prevalence of illness, poor mental health and sleep quality and low energy availability prior to the 2016 Summer Olympic Games." British Journal of Sports Medicine 52, no. 1 (2017): 47–53. http://dx.doi.org/10.1136/bjsports-2017-098208.

Full text
Abstract:
ObjectiveEstablish the prevalence of illness symptoms, poor sleep quality, poor mental health symptoms, low energy availability and stress-recovery state in an Olympic cohort late in the 3 months prior to the Summer Olympic Games.MethodsOlympic athletes (n=317) from 11 sports were invited to complete questionnaires administered 3 months before the Rio 2016 Olympic Games. These questionnaires included the Depression, Anxiety and Stress Questionnaire, Perceived Stress Scale, Dispositional Resilience Scale, Recovery-Stress Questionnaire (REST-Q-52 item), Low Energy Availability in Females Questio
APA, Harvard, Vancouver, ISO, and other styles
16

de la Fuente, Josu, Dirk-Jan Eikema, Paul Bosman, et al. "Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT." Blood 136, Supplement 1 (2020): 45–47. http://dx.doi.org/10.1182/blood-2020-142397.

Full text
Abstract:
Congenital sideroblastic anaemias (CSA) are a rare group of disorders characterized by the presence of pathologic iron deposits within the mitochondria of erythroid precursors (ring sideroblasts) in the bone marrow due to heterogenous germline mutations leading to defects in mitochondrial heme synthesis, iron-sulfur (Fe-S) cluster biogenesis, or protein synthesis. Patients present with anaemia and relative reticulocytopenia, and systemic iron overload secondary to chronic ineffective erythropoiesis, leading to end-organ damage. The disease is heterogenous underlying the genetic variability and
APA, Harvard, Vancouver, ISO, and other styles
17

Scheffold, Annika, Billy Michael Chelliah Jebaraj, Eugen Tausch та ін. "In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model". Blood 128, № 22 (2016): 190. http://dx.doi.org/10.1182/blood.v128.22.190.190.

Full text
Abstract:
Abstract Inhibitors of B-cell receptor (BCR) signaling have proven effective in the treatment of chronic lymphocytic leukemia (CLL). An important downstream mediator of BCR signaling is phosphoinositide 3-kinase delta (PI3Kd), which through activation of AKT, controls cell survival, growth and proliferation. Since it is expressed predominantly in cells of hematopoietic origin, PI3Kd is a promising target in CLL, and the novel PI3Kd inhibitor idelalisib is effective in treating relapsed/refractory CLL. However, a subset of patients relapse under therapy, and the mechanisms leading to resistance
APA, Harvard, Vancouver, ISO, and other styles
18

Langerbeins, Petra, Jasmin Bahlo, Christina Rhein, et al. "Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study." Blood 126, no. 23 (2015): 2934. http://dx.doi.org/10.1182/blood.v126.23.2934.2934.

Full text
Abstract:
Abstract Introduction Observation (watch and wait) is the standard of care for patients with asymptomatic early stage CLL. Prognostic scores can be used to predict the outcome for high-risk subgroups that have rapid disease progression and poor survival. So far early treatment intervention failed to improve survival. However with development of novel targeted drugs treatment of high-risk CLL has improved. Thus, the risk-stratified management of early stage CLL needs to be re-evaluated. The CLL12-trial is the first prospective, placebo-controlled, double-blind, phase 3 trial investigating wheth
APA, Harvard, Vancouver, ISO, and other styles
19

Woyach, Jennifer, Shanmugapriya Thangavadivel, David Weiss, et al. "Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL." Blood 134, Supplement_1 (2019): 1759. http://dx.doi.org/10.1182/blood-2019-131099.

Full text
Abstract:
Introduction: The Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib (IB) is a standard therapy for previously untreated CLL patients. While therapy is currently indicated only for patients with progressive, symptomatic disease, the introduction of targeted therapies in CLL has re-opened the question of whether asymptomatic high risk patients would benefit from early intervention. As well, even in early stages CLL is associated with profound cellular, humoral and innate immune suppression and patients with CLL respond poorly to routine vaccinations. IB has been shown to reverse disease mediate
APA, Harvard, Vancouver, ISO, and other styles
20

Kipps, Thomas J., Peter Hillmen, Fatih Demirkan, et al. "11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies." Blood 128, no. 22 (2016): 2042. http://dx.doi.org/10.1182/blood.v128.22.2042.2042.

Full text
Abstract:
Abstract Background: Patients (pts) with CLL/SLL that have del11q tend to have relatively short remission durations and shorter overall survival (OS) with standard chemotherapy regimens. Ibrutinib (ibr), a first-in-class, oral, once-daily inhibitor of Bruton's tyrosine kinase (BTK) is indicated by the US FDA for the treatment of pts with CLL/SLL and allows for treatment without chemotherapy. In phase 3 studies, treatment with single-agent ibr was superior to treatment with ofatumumab (ofa) in relapsed/refractory (R/R) CLL/SLL (RESONATE; Byrd, N Engl J Med 2013) or chlorambucil (clb) in treatme
APA, Harvard, Vancouver, ISO, and other styles
21

Sanka, Pranavi, Pamela Egan, Rabin Niroula, Inna Yakirevich, David Gardner, and John L. Reagan. "Inpatient Versus Outpatient Administration of Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia." Blood 142, Supplement 1 (2023): 4229. http://dx.doi.org/10.1182/blood-2023-184948.

Full text
Abstract:
Background: Venetoclax (VEN) in combination with hypomethylating agents (HMAs) is the standard of care for newly diagnosed AML patients who are older and determined to be unfit for intensive induction chemotherapy. The decreased intensity of HMA/VEN affords the possibility of outpatient management provided appropriate monitoring can be done for tumor lysis syndrome, persistent cytopenias, and infection risk inherent to initial AML directed therapy. We evaluated the incidence of TLS, infection risk, and transfusion needs in patients with AML treated with HMA/VEN at our institution who initiated
APA, Harvard, Vancouver, ISO, and other styles
22

Abdul Subhan, Achmad Firdaus Firdaus, and Mukhamad Najib. "The Influence of Islamic Service Quality and Trust on Customer Satisfaction and Intention in Reusing The Services in The Implementation of Umrah and Special Hajj Pilgrimage." Jurnal Ekonomi Syariah Teori dan Terapan 10, no. 3 (2023): 275–89. http://dx.doi.org/10.20473/vol10iss20233pp275-289.

Full text
Abstract:
ABSTRACT: Seeing the high potential for Umrah and Special Hajj departures, with a very large number of Umrah and Special Hajj travel, making competition between travel even higher. This study aimed to determine the effect of Islamic service quality and trust on customer satisfaction, which will relate to interest in using it again. The method used in this research was the quantitative exploratory method. The participants in this study were Umrah and Special Hajj pilgrims who are registered with Hajj and Umrah organisers with official permits and domiciled in Java. The sampling technique in thi
APA, Harvard, Vancouver, ISO, and other styles
23

Devos, Timothy, Violaine Havelange, Koen Theunissen, et al. "Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry." Blood 134, Supplement_1 (2019): 4161. http://dx.doi.org/10.1182/blood-2019-127923.

Full text
Abstract:
Background Iclusig (ponatinib) is a third-generation tyrosine kinase inhibitor (TKI) indicated for adult patients with chronic, accelerated or blast phase CML resistant or intolerant to nilotinib or dasatinib or with Ph+ ALL resistant or intolerant to dasatinib or for patients with the T315I mutation. Long-term efficacy and safety of ponatinib have been demonstrated in clinical trials, but real-world data are still limited. Here, we report the data on ponatinib use in CML and Ph+ ALL patients in routine clinical practice collected over 3 years in Belgium. Methods This ongoing prospective regis
APA, Harvard, Vancouver, ISO, and other styles
24

Yeung, David T., Naranie Shanmuganathan, Andrew Grigg, et al. "Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study." Blood 134, Supplement_1 (2019): 2926. http://dx.doi.org/10.1182/blood-2019-125740.

Full text
Abstract:
Pegylated interferon (Peg-IFN) increases molecular response rates when used in combination with imatinib (IM) and dasatinib compared with tyrosine kinase inhibitor (TKI) monotherapy in de novo chronic phase chronic myeloid leukemia (CP-CML). (Preudhomme NEJM 2010, Hjorth-Hansen Leukemia 2016). The phase II Pinnacle (ALLG CML 11) study evaluated the tolerability and molecular response rate of nilotinib (NIL) with Peg-IFN alfa-2B (PegIntron, MSD) in CP-CML patients. Co-primary end points were MMR (BCR-ABL1 ≤ 0.1%) at 12 mths and MR4.5 (BCR-ABL1 ≤ 0.0032%) at 24 mths. Key secondary end points wer
APA, Harvard, Vancouver, ISO, and other styles
25

Neelapu, Sattva S., Michael Dickinson, Matthew L. Ulrickson, et al. "Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)." Blood 136, Supplement 1 (2020): 49. http://dx.doi.org/10.1182/blood-2020-134449.

Full text
Abstract:
Background: Pts with high-risk LBCL have poor outcomes with R-CHOP chemoimmunotherapy (Sathyanarayanan, et al. ASH 2016. #106), and ≈50% of pts will not achieve long-term disease remission (Coiffier, et al. ASH Ed Program. 2016), highlighting unmet need for new therapies. Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, was approved for treatment of adults with R/R LBCL after ≥ 2 lines of systemic therapies based on the pivotal study, ZUMA-1 (Neelapu SS, et al. NEJM. 2017). ZUMA-12 is a Phase 2, multicenter, open-label, single-arm study of axi-cel as part of fir
APA, Harvard, Vancouver, ISO, and other styles
26

Meyer, Everett H., Rasmus Hoeg, Anna Moroz, et al. "Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants." Blood 136, Supplement 1 (2020): 47–48. http://dx.doi.org/10.1182/blood-2020-142974.

Full text
Abstract:
BACKGROUND GVHD remains a frequent and serious complication of HSCT despite the decades-long use of standard immunosuppression, such as tacrolimus and methotrexate, as prophylaxis against GVHD. Preclinical models have shown that the timed infusion of donor-derived high-purity CD4+CD25+FOXP3+ regulatory T cells (Treg) preceding adoptive transfer of conventional T cells (Tcon) prevents GVHD and maintains anti-cancer immunity without the need of pharmacologic agents. Early clinical trials using purified Treg-engineered graft showed safety and feasibility, but more extensive clinical studies are n
APA, Harvard, Vancouver, ISO, and other styles
27

Taranto, Eleanor, Robert A. Redd, Erin Jeter, et al. "Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation." Blood 138, Supplement 1 (2021): 3491. http://dx.doi.org/10.1182/blood-2021-147263.

Full text
Abstract:
Abstract Background: Autologous stem cell transplantation (ASCT) can be curative for a subset of patients (pts) with relapsed/refractory classical Hodgkin lymphoma (cHL). Post-ASCT maintenance therapy with brentuximab vedotin (BV) improves progression-free survival (PFS) among pts with high-risk clinical features, and PD-1 blockade is also being investigated in this setting. Ideally, novel biomarkers could be used to guide pt selection for these post-ASCT therapies. We hypothesized that the presence of minimal residual disease (MRD), quantified using immunoglobulin-based next generation sequen
APA, Harvard, Vancouver, ISO, and other styles
28

Yeung, David T., Andrew Grigg, Naranie Shanmuganathan, et al. "Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study." Blood 134, Supplement_1 (2019): 4150. http://dx.doi.org/10.1182/blood-2019-127619.

Full text
Abstract:
Dasatinib treatment leads to excellent molecular responses in chronic phase chronic myeloid leukemia (CP-CML). Pleural effusions, an adverse event related dasatinib treatment, may lead to intolerance and drug discontinuations. Strategies aimed at minimising this may improve outcomes. In the Phase III Dasision study, pleural effusion affected ~22% of patients after 4 years of dasatinib treatment at 100mg/d (Cortes et al, 2016 JCO 34(20) 2333-40). The elderly are at particular risk (Latagliata et al 2013 Hem Onc 31(2) 103-9), and there is suggestion that higher dasatinib trough (Cmin) levels may
APA, Harvard, Vancouver, ISO, and other styles
29

Mascarenhas, John, Brian Higgins, Doreen Anders, et al. "Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study." Blood 136, Supplement 1 (2020): 29–31. http://dx.doi.org/10.1182/blood-2020-135868.

Full text
Abstract:
Background PV is a clonal myeloid neoplasm characterized by activating mutations in JAK2 and increased red blood cell production. Reduction of thrombosis risk through lowering of hematocrit (Hct) and thus blood viscosity is critical, but management of constitutional symptoms is also important. HU is an effective and well-tolerated first-line treatment (tx) for PV, but pts who develop resistance to or intolerance of HU have limited tx options. A Phase I study of idasanutlin, an MDM2 antagonist leading to increased p53 activity, showed encouraging efficacy and potential disease-modifying effects
APA, Harvard, Vancouver, ISO, and other styles
30

Merz, Maximilian, Vishal Patel, Lucie Kutikova, et al. "Treatment Patterns in Patients (pts) with Refractory/Relapsed Multiple Myeloma (RRMM) in Germany between 2016 and 2018." Blood 134, Supplement_1 (2019): 4734. http://dx.doi.org/10.1182/blood-2019-128030.

Full text
Abstract:
Background: The RRMM treatment landscape has increased in complexity in recent years due to the availability of novel agents. In this study, we evaluated treatment patterns over 3 years in real-world RRMM pts treated with regimens containing one or more of the following agents: carfilzomib (K), bortezomib (V), lenalidomide (R), pomalidomide (P), ixazomib (I), daratumumab (D), and elotuzumab (E). Methods: We retrospectively analysed data from a German longitudinal database (TherapyMonitor) for pts receiving RRMM treatment (2nd-line [2L] and beyond) between January 2016 and December 2018. Patien
APA, Harvard, Vancouver, ISO, and other styles
31

Eyre, Toby A., Nicolas Martinez-Calle, Amy A. Kirkwood, et al. "CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement." Blood 132, Supplement 1 (2018): 1694. http://dx.doi.org/10.1182/blood-2018-99-111010.

Full text
Abstract:
Abstract Introduction Very few studies have assessed the incidence and risk factors associated with CNS progressive disease (PD) in elderly DLBCL. The CNS IPI (international prognostic index) uses the standard IPI with an additional point for renal/adrenal (R/A) involvement to define CNS risk in DLBCL patients (pts). The CNS IPI is validated in younger DLBCL pts (Schmitz et al, 2016) but little is known about CNS risk in the elderly. Few data exist outwith a single study of pts >80 years (y) pooled from 2 LYSA mini CHOP trials (Cabannes-Hamy et al 2018). CNS PD risk from 270 pts >80y was
APA, Harvard, Vancouver, ISO, and other styles
32

Stilgenbauer, Stephan, Franck Morschhauser, Clemens-Martin Wendtner, et al. "Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia." Blood 128, no. 22 (2016): 4393. http://dx.doi.org/10.1182/blood.v128.22.4393.4393.

Full text
Abstract:
Abstract Introduction: The anti-apoptotic protein BCL2 is overexpressed in a number of hematological malignancies, including chronic lymphocytic leukemia (CLL). Venetoclax (VEN) is a selective, oral BCL2 inhibitor with demonstrated activity and an acceptable safety profile both as monotherapy and in combination regimens in relapsed/refractory (R/R) CLL patients (pts). VEN has demonstrated preclinical activity with bendamustine/rituximab (BR), a standard treatment in this population, as well as clinical efficacy with R. The anti-CD20 mAb obinutuzumab (G) has demonstrated improved efficacy in co
APA, Harvard, Vancouver, ISO, and other styles
33

Ochi, *Shohei, Hitoshi Inada, and Noriko Osumi. "AUTOMATED ANALYSIS OF RODENT BEHAVIOR USING INTELLIPROFILLER: A POTENTIAL TOOL FOR STUDYING NEURODEVELOPMENTAL DISORDER-LIKE MODEL MICE." International Journal of Neuropsychopharmacology 28, Supplement_1 (2025): i58—i59. https://doi.org/10.1093/ijnp/pyae059.101.

Full text
Abstract:
Abstract Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder (NDD) characterized by deficits in social communication and repetitive behaviors. With an increased number of children diagnosed with ASD, the need to understand the mechanisms and symptoms of NDDs is growing to develop effective treatments and interventions. Animal models have been instrumental in studying NDDs, employing classical behavioral paradigms such as the open field test and the social interaction test. However, obtaining consistent results is still challenging due to the handling effects of experiment
APA, Harvard, Vancouver, ISO, and other styles
34

Pomares, Helena, Rocio Parody Porras, Alberto Mussetti, et al. "Allogeneic STEM Cell Transplantation in 45 Patients with Myelodysplastic Syndrome: Single-Center Analysis." Blood 138, Supplement 1 (2021): 4913. http://dx.doi.org/10.1182/blood-2021-153333.

Full text
Abstract:
Abstract Background: Myelodysplastic syndromes (MDS) includes a group of clonal myeloid neoplasms characterized by cytopenias due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and an increased risk of transformation to acute myelogenous leukemia (AML). Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapeutic option for patients with MDS. Aim: To analyze the clinical features and evolution of the MDS patients who underwent to HCT in our institution. Methods: Between July 2006 to January 2021, forty-five patients with MDS underwe
APA, Harvard, Vancouver, ISO, and other styles
35

Jaeger, Ulrich, Alexander Egle, Ingrid Simonitsch-Klupp, et al. "Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study." Blood 136, Supplement 1 (2020): 26. http://dx.doi.org/10.1182/blood-2020-136953.

Full text
Abstract:
Background: Patients with diffuse large B-cell lymphoma (DLBCL) relapsing early (within 12 months) or primary refractory to induction therapy with rituximab (R) and CHOP have a poor prognosis with a median overall survival (OS) of less than 2 years. Relapse immuno-chemotherapy followed by autologous stem cell transplantation is the standard of care, but response rates are still not satisfactory and a substantial number of patients are ineligible for transplant or aggressive therapies. Novel antibodies, small molecules and CAR-T cell therapies have been explored for this population. We initiate
APA, Harvard, Vancouver, ISO, and other styles
36

Rawstron, Andy C., Talha Munir, Samuel Muñoz-Vicente, et al. "Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study." Blood 128, no. 22 (2016): 2049. http://dx.doi.org/10.1182/blood.v128.22.2049.2049.

Full text
Abstract:
Abstract Background: A major aim of treatment in CLL is to eradicate detectable minimal residual disease (MRD). Ibrutinib is a major step forward in the treatment of CLL but results in an immediate lymphocytosis that persists in most patients for at least several months. Obinutuzumab is a second generation anti-CD20 monoclonal antibody which appears to be highly effective in CLL resulting in a rapid eradication of peripheral blood lymphocytosis and the eradication of MRD in a proportion of patients. The IcICLLe Extension Study expands on the IcICLLe trial (ISRCTN 12695354) to examine the effic
APA, Harvard, Vancouver, ISO, and other styles
37

Riebenbauer, Katharina, Stefan Czerny, Maximilian Egg, et al. "The changing epidemiology of human leishmaniasis in the non-endemic country of Austria between 2000 to 2021, including a congenital case." PLOS Neglected Tropical Diseases 18, no. 1 (2024): e0011875. http://dx.doi.org/10.1371/journal.pntd.0011875.

Full text
Abstract:
Background Leishmaniasis is caused by infection with intracellular protozoans of the genus Leishmania. Transmission occurs predominantly by the bite of phlebotomine sandflies, other routes, including congenital transmission, are rare. The disease manifests as either cutaneous, visceral or mucosal/mucocutaneous leishmaniasis. In recent years, changes in the epidemiological pattern have been reported from Europe. Principal findings A total of 311 new and 29 published leishmaniasis cases occurring between 01/01/2000 and 12/31/2021 in Austria were collected and analyzed. These encompassed 146 cuta
APA, Harvard, Vancouver, ISO, and other styles
38

Croft, James, Andrew Hall, Katrina Walker, et al. "Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial." Blood 132, Supplement 1 (2018): 3274. http://dx.doi.org/10.1182/blood-2018-99-111835.

Full text
Abstract:
Abstract Background and aims Treatment of relapsed/refractory myeloma (RRMM) remains a challenge as most approved and commonly accessible doublet treatments induce responses (≥PR) in less than half of patients. The combination of the classical alkylator cyclophosphamide with thalidomide (CTD) or lenalidomide (CRD) is standard of care in early lines of therapy in the UK and elsewhere. Data on the clinical value of cyclophosphamide and pomalidomide combination therapy in RRMM is currently sparse and lacking for patients that have previously been treated with cyclophosphamide in earlier lines of
APA, Harvard, Vancouver, ISO, and other styles
39

Dreyling, Martin, Armando Santoro, Luigina Mollica, et al. "Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma." Blood 132, Supplement 1 (2018): 1595. http://dx.doi.org/10.1182/blood-2018-99-114842.

Full text
Abstract:
Abstract Introduction: We have previously reported that treatment of patients with relapsed or refractory indolent B-cell lymphoma with the pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor copanlisib resulted in durable responses with a manageable safety profile (Dreyling et al., J Clin Oncol 35:3898-3905, 2017). The objective response rate was 59%. In contrast with oral PI3K inhibitors, there was also a low incidence of severe adverse events, such as pneumonitis and colitis with copanlisib, possibly due to intravenous dosing and intermittent dose schedule. Because late-onset severe
APA, Harvard, Vancouver, ISO, and other styles
40

Fiedler, Walter, Michael Heuser, Jörg Chromik, et al. "Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML." Blood 128, no. 22 (2016): 341. http://dx.doi.org/10.1182/blood.v128.22.341.341.

Full text
Abstract:
Abstract Background:Acute myeloid leukemia (AML) is the second most common form of leukemia and the most frequent cause of leukemia-related deaths in the US. While complete response (CR) rates can be as high as 80% in patients (pts) undergoing initial induction chemotherapy, the majority of pts relapse. Pts who relapse or who fail to achieve CR after first cycle of induction therapy have a bleak prognosis. Selinexor inhibits the major nuclear transport protein exportin (XPO1), which is overexpressed in many cancers. Hematological neoplasms are particularly susceptible to inhibition of XPO1 and
APA, Harvard, Vancouver, ISO, and other styles
41

Durie, Brian GM, Antje Hoering, Rachael Sexton, et al. "Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)." Blood 132, Supplement 1 (2018): 1992. http://dx.doi.org/10.1182/blood-2018-99-117003.

Full text
Abstract:
Abstract Background: SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). The primary end point was progression-free survival (PFS) using a pre-specified one-sided stratified log rank test at a significance level of 0.02. The stratification factors were International Staging System (ISS) stage (I, II or III) and intent to transplant (yes or no), among a total of 6 strata. Overall response rate (ORR), overall survival (OS) and safety were secondary end points. Results of the primary analysis of this trial w
APA, Harvard, Vancouver, ISO, and other styles
42

Hillmen, Peter, Andy Rawstron, Kristian Brock, et al. "Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study." Blood 132, Supplement 1 (2018): 182. http://dx.doi.org/10.1182/blood-2018-182.

Full text
Abstract:
Abstract BACKGROUND Antigen-mediated proliferation and Bcl-2 mediated survival are key to chronic lymphocytic leukemia (CLL) pathogenesis. Ibrutinib is an oral BTK inhibitor affecting antigen-induced proliferation and cell adhesion/migration whilst venetoclax is a potent, highly selective, orally bioavailable Bcl-2 inhibitor affecting CLL cell survival. The treatment of CLL has been revolutionized by these targeted therapies. Both significantly improve survival in CLL but rarely lead to eradication of detectable minimal residual disease (MRD) when given as single agents. The Bloodwise TAP CLAR
APA, Harvard, Vancouver, ISO, and other styles
43

Dimopoulos, Meletios A., Maria Roussou, Maria Gavriatopoulou, et al. "Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival." Blood 128, no. 22 (2016): 4492. http://dx.doi.org/10.1182/blood.v128.22.4492.4492.

Full text
Abstract:
Abstract Renal failure (RF) is a common severe complication of symptomatic myeloma and may be severe enough to require extrarenal dialysis in approximately 1-5% of newly diagnosed patients. Severe RF is associated with high risk of early death and increased morbidity. Immediate effective anti-myeloma therapy and vigorous supportive care are the cornerstones of management. The use of high cutoff hemodialysis to rapidly reduce the load of nephrotoxic light chains seems to offer limited additional benefit in patients requiring dialysis when treated with bortezomib-based therapies (Cook M et al EH
APA, Harvard, Vancouver, ISO, and other styles
44

Mascarenhas, John O., Josef T. Prchal, Alessandro Rambaldi, et al. "Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia." Blood 128, no. 22 (2016): 479. http://dx.doi.org/10.1182/blood.v128.22.479.479.

Full text
Abstract:
Abstract Background: Cytoreductive therapy with hydroxyurea (HU) has been considered first line therapy for patients with high risk polycythemia vera (PV) and essential thrombocythemia (ET) since the results of the PVSG-08 trial demonstrated thrombotic risk reduction (Fruchtman SM et al 1997) for PV and PT1 for ET (Harrison CN et al 2005). Although HU is well tolerated by most patients and has been shown to reduce thrombotic risk in this setting, concern regarding the leukemogenic potential of this oral ribonucleotide reductase inhibitor balanced by the observation of molecular responses with
APA, Harvard, Vancouver, ISO, and other styles
45

Jimenez-Zepeda, Victor, Peter Duggan, Paola Neri, et al. "Early Relapse Following ASCT for Patients with MM: Identification of Predictor Factors in the Era of Novel Agents." Blood 128, no. 22 (2016): 5818. http://dx.doi.org/10.1182/blood.v128.22.5818.5818.

Full text
Abstract:
Abstract Introduction Auto-SCT, still remains as the standard therapy for patients with MM deemed to be eligible for this approach. Unfortunately, even when most patients will respond to auto-SCT, 10-20% of cases will progress within a year. Over the last few years, a dramatic improvement on clinical outcomes has been made by using novel agents in the treatment of MM. Based on the above mentioned, we aimed to assess the incidence of Early Relapse (ER) for patients undergoing auto-SCT treated with novel-agents induction combinations at our center and to explore possible predictor factors. Metho
APA, Harvard, Vancouver, ISO, and other styles
46

Nenoff, Pietro, Shyam B. Verma, Andreas Ebert, et al. "Spread of Terbinafine-Resistant Trichophyton mentagrophytes Type VIII (India) in Germany–“The Tip of the Iceberg?”." Journal of Fungi 6, no. 4 (2020): 207. http://dx.doi.org/10.3390/jof6040207.

Full text
Abstract:
Chronic recalcitrant dermatophytoses, due to Trichophyton (T.) mentagrophytes Type VIII are on the rise in India and are noteworthy for their predominance. It would not be wrong to assume that travel and migration would be responsible for the spread of T. mentagrophytes Type VIII from India, with many strains resistant to terbinafine, to other parts of the world. From September 2016 until March 2020, a total of 29 strains of T. mentagrophytes Type VIII (India) were isolated. All patients were residents of Germany: 12 females, 15 males and the gender of the remaining two was not assignable. Pat
APA, Harvard, Vancouver, ISO, and other styles
47

Wuchter, Patrick, Uta Bertsch, Hans-Juergen Salwender, et al. "Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial." Blood 128, no. 22 (2016): 3373. http://dx.doi.org/10.1182/blood.v128.22.3373.3373.

Full text
Abstract:
Abstract Introduction: The German-Speaking Myeloma Multicenter Group (GMMG) has initiated a randomized multicenter phase III trial on the effect of elotuzumab in VRD (bortezomib, lenalidomide, dexamethasone) induction/consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (GMMG-HD6 trial, NCT02495922). The study compares four cycles induction therapy with VRD vs. VRD + elotuzumab, followed by standard intensification (i.e. mobilization and stem cell transplantation), two cycles consolidation with VRD/VRD + elotuzumab and lenalidomide maintenance +/- elotuz
APA, Harvard, Vancouver, ISO, and other styles
48

Arora, R., R. U. Rahman, W. Joe, et al. "Families of Children Newly Diagnosed With Cancer Incur Significant Out-of-Pocket Expenditure for Treatment: Report of a Multi-Site Prospective Longitudinal Study From India (INPOG-ACC-16-01)." Journal of Global Oncology 4, Supplement 2 (2018): 74s. http://dx.doi.org/10.1200/jgo.18.42400.

Full text
Abstract:
Background: Diagnosis of cancer in a child places considerable economic burden on families. The health expenditures are more catastrophic in resource limited countries like India where GDP spend on health is just over 1% and financing of treatment is usually out-of-pocket (OOP). Consequently parents may abandon their child's cancer treatment to ensure financial sustainability of the family. Research in this area is mostly from resource rich countries and OOP expenditure burden remains unknown in India. Aim: The objective of this study is to describe the OOP expenditure incurred by families of
APA, Harvard, Vancouver, ISO, and other styles
49

Clement-Filliatre, Lauriane, Lotfi Benboubker, Anne-Marie Stoppa, et al. "Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study." Blood 136, Supplement 1 (2020): 25–26. http://dx.doi.org/10.1182/blood-2020-133807.

Full text
Abstract:
Background Ixazomib (IXA) is an orally-administered proteasome inhibitor approved in Europe in November 2016 for relapsed and/or refractory multiple myeloma (RRMM). It became available in France in May 2017 via a compassionate use program (CUP) and from October 2018 via the classical market access (non-CUP). In addition to pivotal clinical trials, real-world evidence (RWE) is required to evaluate effectiveness and safety in clinical routine practices. A non-interventional study, has been conducting in France to evaluate IXA use in combination with lenalidomide and dexamethasone (IRD) in real l
APA, Harvard, Vancouver, ISO, and other styles
50

Yong, Michelle K., Shio Yen Tio, Jake Valentine, et al. "The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation." Blood 134, Supplement_1 (2019): 3437. http://dx.doi.org/10.1182/blood-2019-128227.

Full text
Abstract:
Introduction Understanding the economic impact of managing allogeneic hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) is important for future planning within institutional transplant programs. CMV remains the most frequent viral infection following HSCT of which the clinical impact on transplant outcomes has been well described. However, much less is known about the impact of CMV on health resource utilisation, re-admissions and hospital costs. In addition to antiviral therapy, there are nursing, medical and pharmacy costs to consider. We therefore undertook a s
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography